DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Corzide (Nadolol / Bendroflumethiazide) - Side Effects and Adverse Reactions

 
 



ADVERSE REACTIONS

Nadolol

Most adverse effects have been mild and transient and have rarely required withdrawal of therapy.

Cardiovascular—Bradycardia with heart rates of less than 60 beats per minute occurs commonly, and heart rates below 40 beats per minute and/or symptomatic bradycardia were seen in about 2 of 100 patients. Symptoms of peripheral vascular insufficiency, usually of the Raynaud type, have occurred in approximately 2 of 100 patients. Cardiac failure, hypotension, and rhythm/conduction disturbances have each occurred in about 1 of 100 patients. Single instances of first degree and third degree heart block have been reported; intensification of AV block is a known effect of beta-blockers (see also CONTRAINDICATIONS, WARNINGS, and PRECAUTIONS).

Central Nervous System—Dizziness or fatigue has been reported in approximately 2 of 100 patients; paresthesias, sedation, and change in behavior have each been reported in approximately 6 of 1000 patients.

Respiratory—Bronchospasm has been reported in approximately 1 of 1000 patients (see CONTRAINDICATIONS and WARNINGS).

Gastrointestinal—Nausea, diarrhea, abdominal discomfort, constipation, vomiting, indigestion, anorexia, bloating, and flatulence have been reported in 1 to 5 of 1000 patients.

Miscellaneous—Each of the following has been reported in 1 to 5 of 1000 patients: rash; pruritus; headache; dry mouth, eyes, or skin; impotence or decreased libido; facial swelling; weight gain; slurred speech; cough; nasal stuffiness; sweating; tinnitus; blurred vision. Reversible alopecia has been reported infrequently.

The following adverse reactions have been reported in patients taking nadolol and/or other beta-adrenergic blocking agents, but no causal relationship to nadolol has been established.

Central Nervous System—Reversible mental depression progressing to catatonia; visual disturbances; hallucinations; an acute reversible syndrome characterized by disorientation for time and place, short-term memory loss, emotional lability with slightly clouded sensorium, and decreased performance on neuropsychometrics.

Gastrointestinal—Mesenteric arterial thrombosis; ischemic colitis; elevated liver enzymes.

Hematologic—Agranulocytosis; thrombocytopenic or nonthrombocytopenic purpura.

Allergic—Fever combined with aching and sore throat; laryngospasm; respiratory distress.

Miscellaneous—Pemphigoid rash; hypertensive reaction in patients with pheochromocytoma; sleep disturbances; Peyronie's disease.

The oculomucocutaneous syndrome associated with the beta-blocker practolol has not been reported with nadolol.

Bendroflumethiazide

Gastrointestinal—Nausea, vomiting, cramping and anorexia are not uncommon; diarrhea, constipation, gastric irritation, abdominal bloating, jaundice (intrahepatic cholestatic jaundice), hepatitis, and sialadenitis occasionally occur; and pancreatitis has been reported.

Central Nervous System—Dizziness, vertigo, paresthesia, headache, and xanthopsia occasionally occur.

Hematologic—Leukopenia, agranulocytosis, thrombocytopenia, hemolytic anemia, and aplastic anemia have been reported.

Dermatologic-Hypersensitivity—Purpura, exfoliative dermatitis, pruritus, ecchymosis, urticaria, necrotizing angiitis (vasculitis, cutaneous vasculitis), respiratory distress including pneumonitis, fever, and anaphylactic reactions occasionally occur; photosensitivity and rash have been reported.

Cardiovascular—Orthostatic hypotension may occur and may be potentiated by coadministration with certain other drugs (e.g., alcohol, barbiturates, narcotics, other antihypertensive medications, etc.; see PRECAUTIONS, Drug Interactions).

Other—Muscle spasm, weakness, or restlessness is not uncommon; hyperglycemia, glycosuria, metabolic acidosis in diabetic patients, hyperuricemia, allergic glomerulonephritis, and transient blurred vision occasionally occur.

Whenever adverse reactions are moderate or severe, thiazide dosage should be reduced or therapy withdrawn.



REPORTS OF SUSPECTED CORZIDE SIDE EFFECTS / ADVERSE REACTIONS

Below is a sample of reports where side effects / adverse reactions may be related to Corzide. The information is not vetted and should not be considered as verified clinical evidence.

Possible Corzide side effects / adverse reactions in 65 year old male

Reported by a health professional (non-physician/pharmacist) from United Kingdom on 2012-02-23

Patient: 65 year old male

Reactions: Dyspnoea, Crepitations, Atrial Fibrillation, Renal Failure Acute, Lower Respiratory Tract Infection, Arrhythmia

Adverse event resulted in: hospitalization

Suspect drug(s):
Zytiga
    Dosage: 1 g, unk
    Administration route: Oral
    Indication: Prostate Cancer Metastatic
    Start date: 2012-01-16

Ramipril
    Dosage: 2.5 mg, 1x/day
    Administration route: Oral
    End date: 2012-01-31

Corzide
    Dosage: 5 mg, 1x/day
    End date: 2012-01-31

Other drugs received by patient: Oxycodone; Lansoprazole; Goserelin; Metoclopramide



Possible Corzide side effects / adverse reactions in 65 year old male

Reported by a health professional (non-physician/pharmacist) from United Kingdom on 2012-02-27

Patient: 65 year old male

Reactions: Dyspnoea, Crepitations, Atrial Fibrillation, Condition Aggravated, Lower Respiratory Tract Infection, Renal Failure Acute, Arrhythmia

Adverse event resulted in: hospitalization

Suspect drug(s):
Corzide
    Dosage: 5 mg, qd
    End date: 2012-01-31

Ramipril
    Dosage: 2.5 mg, qd
    Administration route: Oral
    End date: 2012-01-31

Abiraterone
    Dosage: 1 g, unk
    Administration route: Oral
    Indication: Prostate Cancer Metastatic
    Start date: 2012-01-16

Other drugs received by patient: Lansoprazole; Oxycodone HCL; Goserelin; Metoclopramide



Possible Corzide side effects / adverse reactions in 65 year old male

Reported by a health professional (non-physician/pharmacist) from United Kingdom on 2012-02-28

Patient: 65 year old male

Reactions: Dyspnoea, Atrial Fibrillation, Crepitations, Arrhythmia, Lower Respiratory Tract Infection, Renal Failure Acute

Adverse event resulted in: hospitalization

Suspect drug(s):
Corzide
    Indication: Product Used FOR Unknown Indication
    End date: 2012-01-31

Abiraterone Acetate
    Administration route: Oral
    Indication: Prostate Cancer Metastatic
    Start date: 2012-01-16

Ramipril
    Administration route: Oral
    Indication: Product Used FOR Unknown Indication
    End date: 2012-01-31

Other drugs received by patient: Metoclopramide; Goserelin; Oxycodone HCL; Lansoprazole



See index of all Corzide side effect reports >>

Drug label data at the top of this Page last updated: 2014-05-20

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017